---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060243"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T13:59:33.735965+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lyra reports Q3 net loss $15.7M; Phase 2 CT data shows objective improvement in CRS

## Summary
- CT data for LYR-220: ethmoid sinus opacification improved vs sham (p=0.035) at 24 weeks.
- SNOT-22 improvement maintained at Week 28: -17.6 points (p=0.007) vs sham.
- Cash, equivalents and investments $102.6M, sufficient into Q1 2025.
- ENLIGHTEN I Phase 3 fully enrolled; topline results expected 1H 2024.
- Net loss $15.7M vs $14.8M year-over-year; R&D spend up to $12.4M.

## SEC filing metadata
- accession: 0000950170-23-060243
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017023060243/0000950170-23-060243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017023060243/lyra-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060243
- JSON: https://secwatch.observer/filing/0000950170-23-060243.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060243.txt

## Key facts
- Earnings Releases
  Lyra Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017023060243/0000950170-23-060243-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.